Your browser doesn't support javascript.
loading
Targeting the Residual Leukemia Cells after Chemotherapy.
Vu, Ly P; Kharas, Michael G.
Afiliação
  • Vu LP; Molecular Pharmacology Program and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Kharas MG; Molecular Pharmacology Program and Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: kharasm@mskcc.org.
Cancer Cell ; 34(3): 353-355, 2018 09 10.
Article em En | MEDLINE | ID: mdl-30205040
One of the biggest challenges in treating acute myeloid leukemia (AML) is relapse of aggressive disease after treatment. In this issue of Cancer Cell, Boyd et al. characterize a molecularly distinct population of chemotherapy-induced transient leukemic regenerating cells (LRCs), which can be exploited to prevent AML recurrence.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Antineoplásicos Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Antineoplásicos Idioma: En Ano de publicação: 2018 Tipo de documento: Article